Sanofi sales hit by currencies and slowing diabetes revenues

31 July 2018

French pharma major Sanofi (Euonext: SAN) released second-quarter 2018 financial results this morning, showing that sales were 8.176 billion euros ($9.57 billion), down 5.7% on a reported basis. Exchange rate movements had a negative effect of 5.8 percentagepoints mainly driven by the movement of the US dollar. At constant exchange rates company sales increased 0.1%.

Second-quarter business net income was up 0.4% at constant exchange rates at 1.558 billion euros, with business earnings per share (EPS) rising 1.5% to 1.25 euros.

Analysts polled by Reuters in partnership with Inquiry Financial had on average been expecting a business net income of 1.536 billion euros on revenue of 8.279 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK